Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

United Therapeutics (UTHR) Cash from Operations (2016 - 2026)

United Therapeutics' Cash from Operations history spans 17 years, with the latest figure at 346200000.0 for Q4 2025.

On a quarterly basis, Cash from Operations rose 1.47% to 346200000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1561200000.0, a 17.64% increase, with the full-year FY2025 number at 1561200000.0, up 17.64% from a year prior.
Cash from Operations hit 346200000.0 in Q4 2025 for United Therapeutics, down from 562100000.0 in the prior quarter.
Over the last five years, Cash from Operations for UTHR hit a ceiling of 562100000.0 in Q3 2025 and a floor of 89800000.0 in Q1 2021.
Historically, Cash from Operations has averaged 263350000.0 across 5 years, with a median of 245400000.0 in 2022.
Biggest five-year swings in Cash from Operations: crashed 58.15% in 2021 and later surged 221.49% in 2022.
Tracing UTHR's Cash from Operations over 5 years: stood at 174600000.0 in 2021, then fell by 26.58% to 128200000.0 in 2022, then grew by 17.55% to 150700000.0 in 2023, then skyrocketed by 126.41% to 341200000.0 in 2024, then rose by 1.47% to 346200000.0 in 2025.
Business Quant data shows Cash from Operations for UTHR at 346200000.0 in Q4 2025, 562100000.0 in Q3 2025, and 191700000.0 in Q2 2025.